The global Viral Vector Production (Research-use) market size is expected to be worth around US$ 5.9 billion by 2030, according to a new report by Vision Research Reports.
The global Viral Vector Production (Research-use) market size was valued at US$ 995.0 Mn in 2020 and is anticipated to grow at a CAGR of 20.8% during forecast period 2021 to 2030.
Growth Factors
The expanding research base for advanced therapies has primarily driven the market for research applications including preclinical, clinical, and investigational studies.
The outbreak of the COVID-19 pandemic has created lucrative opportunities for the market players, particularly in the vaccine manufacturing sector. The application of viral vectors in vaccine development against SARS-CoV-2 has witnessed remarkable growth in the fiscal year 2020. By far, the manufacturing of viral vectors for research use is impeded by a lack of production capacity to fulfill the growing market needs.
Thus, operating key stakeholders are engaged in implementing new approaches to overcome these challenges and expand production capacities. The improving ratio of clinical success to the number of clinical trials of gene and cell therapy products is a testament to the enhancing manufacturing capabilities.
Report Coverage
Report Scope | Details |
Market Size | USD 5.9 billion by 2030 |
Growth Rate | CAGR of 20.8% From 2021 to 2030 |
Base Year | 2020 |
Historic Data | 2017 to 2020 |
Forecast Period | 2021 to 2030 |
Segments Covered | Vector Type, Application, Workflow, End-use |
Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
Companies Mentioned | Merck KGaA, Lonza, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Cobra Biologics Ltd., Thermo Fisher Scientific, Waisman Biomanufacturing, Genezen |
Report Highlights
The AAV segment dominated the market for viral vector production (research-use) and accounted for the largest revenue share of 25.0%. The adenovirus segment accounted for a significant revenue share in 2020 owing to the increased employment in covid-19 research. Research institutes such as the University of Oxford, CanSino Biologics, and Johnson and Johnson are engaged in adenoviral vector-based vaccine R&D for SARS-CoV-2. Similarly, the German Center for Infection Research has used attenuated measles vaccine strain for the development of the COVID-19 vaccine.
Lentiviral vectors have witnessed huge success in reprogramming induced Pluripotent Stem Cells (iPSC). This has created opportunities for therapeutic research using iPSC technology. Researchers are also deciphering the potential of Non-integrating lentiviral vectors (NILVs) as a tool to avoid insertional mutagenesis, resulting in the fastest growth of this segment.
The vaccine development segment dominated the market for viral vector production (research-use) and accounted for the largest revenue share of nearly 30.0% in 2020 owing to the tremendous increase in research activity for vaccine development against COVID-19 infection. As a response to the ongoing pandemic, a substantial number of research groups have been working on the development of viral vector-based vaccines.
Viral vectors have been thoroughly studied in various animal models and several viruses have been explored as vaccine vectors eventually entering clinical development. Adenovirus and vaccinia virus are some of the most commonly used viral vectors for vaccine development, owing to their high potential for inducing a strong immune response against a foreign body.
The downstream processing segment dominated the market for viral vector production (research-use) and accounted for the largest revenue share of 55.3% in 2020. Given the growing need for vectors in gene and cell therapy production, the processing and supply of viral vectors are of utmost importance in the research setting, to maintain product quality and yield. This has led to the need for optimizing downstream and upstream processing. The companies are evaluating advanced platforms to overcome the bottleneck in manufacturing.
The downstream processing segment held a significant share in 2020 owing to the highly complex procedures administered to generate polished and purified clinical-grade final products. Also, the high cost associated with purification techniques has led to the high revenue generation in this segment.
The research institutes segment dominated the market for viral vector production (research-use) and accounted for the largest revenue share of 60.0% in 2020. This can be attributed to the high involvement of the global research community in the development of advanced therapies for the treatment of several genetic and acquired diseases that previously lacked an effective treatment paradigm.
The outbreak of the COVID-19 infection has encouraged the research community to shift their focus on the development of a vaccine against the disease in urgency. This increased the demand for viral vectors by the research institutes. Apart from COVID-19, the researchers are engaged in R&D in vaccinology for diseases such as HIV and Hepatitis B, thus leading to significant revenue growth.
North America dominated the viral vector production (research-use) market and accounted for the largest revenue share of 50.0% in 2020. The rapidly growing number of advanced therapy products entering clinical trials, coupled with the presence of key operating players in the region, is the major driving factor for the dominance of the region. the number of cell and gene therapies in the pipeline (phase III trials) reached 362 in the U.S, according to PhRMA. The number is expected to increase twofold if the preclinical pipeline is considered. This growing number depicts the increasing research activity in this space.
Key Players
Market Segmentation
Vector Type Outlook
Application Outlook
Workflow Outlook
End-use Outlook
Regional Outlook
The Viral Vector Production (Research-use) market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report provides size (in terms of volume and value) of Viral Vector Production (Research-use) market for the base year 2020 and the forecast between 2021 and 2030. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
This report focuses on the global Viral Vector Production (Research-use) market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Viral Vector Production (Research-use) market development in United States, Europe and China.
It is pertinent to consider that in a volatile global economy, we haven’t just conducted Viral Vector Production (Research-use) market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.
In terms of production side, this report researches the Viral Vector Production (Research-use) capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and type.
In terms of consumption side, this report focuses on the consumption of Viral Vector Production (Research-use) by regions (countries) and application.
Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Viral Vector Production (Research-use) market. These figures have been provided in terms of both revenue and volume for the period 2017 to 2030. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Viral Vector Production (Research-use) market companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Viral Vector Production (Research-use) market upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of market and consumption, major regions and Consumption, major Chinese producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The research in this report also includes product parameters, production process, cost structure, and data information classified by region, technology and application. Finally, the paper model new project SWOT analysis and investment feasibility study of the case model.
Overall, this is an in-depth research report specifically for the Viral Vector Production (Research-use) industry. The research center uses an objective and fair way to conduct an in-depth analysis of the development trend of the industry, providing support and evidence for customer competition analysis, development planning, and investment decision-making. In the course of operation, the project has received support and assistance from technicians and marketing personnel in various links of the industry chain.
Viral Vector Production (Research-use) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Viral Vector Production (Research-use) market.
Prominent players in the market are predicted to face tough competition from the new entrants. However, some of the key players are targeting to acquire the startup companies in order to maintain their dominance in the global market. For a detailed analysis of key companies, their strengths, weaknesses, threats, and opportunities are measured in the report by using industry-standard tools such as the SWOT analysis. Regional coverage of key companies is covered in the report to measure their dominance. Key manufacturers of Viral Vector Production (Research-use) market are focusing on introducing new products to meet the needs of the patrons. The feasibility of new products is also measured by using industry-standard tools.
Key companies are increasing their investments in research and development activities for the discovery of new products. There has also been a rise in the government funding for the introduction of new Viral Vector Production (Research-use) market. These factors have benefited the growth of the global market for Viral Vector Production (Research-use). Going forward, key companies are predicted to benefit from the new product launches and the adoption of technological advancements. Technical advancements have benefited many industries and the global industry is not an exception.
New product launches and the expansion of already existing business are predicted to benefit the key players in maintaining their dominance in the global market for Viral Vector Production (Research-use). The global market is segmented on the basis of region, application, en-users and product type. Based on region, the market is divided into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA).
In this study, the years considered to estimate the market size of Viral Vector Production (Research-use) are as follows:
Reasons to Purchase this Report:
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Market Size Estimation
Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users).
The market estimations in this report are based on the selling price (excluding any discounts provided by the manufacturer, distributor, wholesaler or traders). Market share analysis, assigned to each of the segments and regions are achieved through product utilization rate and average selling price.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or others factors are accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Vision Research Reports and presented in this report.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation. Extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report.
Secondary Sources
Secondary Sources occupies approximately 25% of data sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on. This research study includes secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; investor presentations; and SEC filings of companies.
Primary Sources
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
The study objectives of this report are:
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Viral Vector Production (Research-use) Market, By Vector Type
7.1. Viral Vector Production (Research-use) Market, by Vector Type, 2021-2030
7.1.1. Adeno-associated virus (AAV)
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Lentivirus
7.1.2.1. Market Revenue and Forecast (2017-2030)
7.1.3. Adenovirus
7.1.3.1. Market Revenue and Forecast (2017-2030)
7.1.4. Retrovirus
7.1.4.1. Market Revenue and Forecast (2017-2030)
7.1.5. Others
7.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Viral Vector Production (Research-use) Market, By Application
8.1. Viral Vector Production (Research-use) Market, by Application, 2021-2030
8.1.1. Cell & Gene Therapy Development
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Vaccine Development
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Biopharmaceutical and Pharmaceutical Discovery
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Biomedical Research
8.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Viral Vector Production (Research-use) Market, By Workflow
9.1. Viral Vector Production (Research-use) Market, by Workflow, 2021-2030
9.1.1. Upstream Processing
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Downstream Processing
9.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Viral Vector Production (Research-use) Market, By End-use
10.1. Viral Vector Production (Research-use) Market, by End-use, 2021-2030
10.1.1. Pharmaceutical and Biopharmaceutical Companies
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Research Institutes
10.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Viral Vector Production (Research-use) Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Vector Type (2017-2030)
11.1.2. Market Revenue and Forecast, by Application (2017-2030)
11.1.3. Market Revenue and Forecast, by Workflow (2017-2030)
11.1.4. Market Revenue and Forecast, by End-use (2017-2030)
11.1.5. U.S.
11.1.5.1. Market Revenue and Forecast, by Vector Type (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.1.5.3. Market Revenue and Forecast, by Workflow (2017-2030)
11.1.5.4. Market Revenue and Forecast, by End-use (2017-2030)
11.1.6. Rest of North America
11.1.6.1. Market Revenue and Forecast, by Vector Type (2017-2030)
11.1.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.1.6.3. Market Revenue and Forecast, by Workflow (2017-2030)
11.1.6.4. Market Revenue and Forecast, by End-use (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Vector Type (2017-2030)
11.2.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.3. Market Revenue and Forecast, by Workflow (2017-2030)
11.2.4. Market Revenue and Forecast, by End-use (2017-2030)
11.2.5. UK
11.2.5.1. Market Revenue and Forecast, by Vector Type (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.5.3. Market Revenue and Forecast, by Workflow (2017-2030)
11.2.5.4. Market Revenue and Forecast, by End-use (2017-2030)
11.2.6. Germany
11.2.6.1. Market Revenue and Forecast, by Vector Type (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.6.3. Market Revenue and Forecast, by Workflow (2017-2030)
11.2.6.4. Market Revenue and Forecast, by End-use (2017-2030)
11.2.7. France
11.2.7.1. Market Revenue and Forecast, by Vector Type (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.7.3. Market Revenue and Forecast, by Workflow (2017-2030)
11.2.7.4. Market Revenue and Forecast, by End-use (2017-2030)
11.2.8. Rest of Europe
11.2.8.1. Market Revenue and Forecast, by Vector Type (2017-2030)
11.2.8.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.8.3. Market Revenue and Forecast, by Workflow (2017-2030)
11.2.8.4. Market Revenue and Forecast, by End-use (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Vector Type (2017-2030)
11.3.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.3. Market Revenue and Forecast, by Workflow (2017-2030)
11.3.4. Market Revenue and Forecast, by End-use (2017-2030)
11.3.5. India
11.3.5.1. Market Revenue and Forecast, by Vector Type (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.5.3. Market Revenue and Forecast, by Workflow (2017-2030)
11.3.5.4. Market Revenue and Forecast, by End-use (2017-2030)
11.3.6. China
11.3.6.1. Market Revenue and Forecast, by Vector Type (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.6.3. Market Revenue and Forecast, by Workflow (2017-2030)
11.3.6.4. Market Revenue and Forecast, by End-use (2017-2030)
11.3.7. Japan
11.3.7.1. Market Revenue and Forecast, by Vector Type (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.7.3. Market Revenue and Forecast, by Workflow (2017-2030)
11.3.7.4. Market Revenue and Forecast, by End-use (2017-2030)
11.3.8. Rest of APAC
11.3.8.1. Market Revenue and Forecast, by Vector Type (2017-2030)
11.3.8.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.8.3. Market Revenue and Forecast, by Workflow (2017-2030)
11.3.8.4. Market Revenue and Forecast, by End-use (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Vector Type (2017-2030)
11.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.3. Market Revenue and Forecast, by Workflow (2017-2030)
11.4.4. Market Revenue and Forecast, by End-use (2017-2030)
11.4.5. GCC
11.4.5.1. Market Revenue and Forecast, by Vector Type (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.5.3. Market Revenue and Forecast, by Workflow (2017-2030)
11.4.5.4. Market Revenue and Forecast, by End-use (2017-2030)
11.4.6. North Africa
11.4.6.1. Market Revenue and Forecast, by Vector Type (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.6.3. Market Revenue and Forecast, by Workflow (2017-2030)
11.4.6.4. Market Revenue and Forecast, by End-use (2017-2030)
11.4.7. South Africa
11.4.7.1. Market Revenue and Forecast, by Vector Type (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.7.3. Market Revenue and Forecast, by Workflow (2017-2030)
11.4.7.4. Market Revenue and Forecast, by End-use (2017-2030)
11.4.8. Rest of MEA
11.4.8.1. Market Revenue and Forecast, by Vector Type (2017-2030)
11.4.8.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.8.3. Market Revenue and Forecast, by Workflow (2017-2030)
11.4.8.4. Market Revenue and Forecast, by End-use (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Vector Type (2017-2030)
11.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.5.3. Market Revenue and Forecast, by Workflow (2017-2030)
11.5.4. Market Revenue and Forecast, by End-use (2017-2030)
11.5.5. Brazil
11.5.5.1. Market Revenue and Forecast, by Vector Type (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.5.5.3. Market Revenue and Forecast, by Workflow (2017-2030)
11.5.5.4. Market Revenue and Forecast, by End-use (2017-2030)
11.5.6. Rest of LATAM
11.5.6.1. Market Revenue and Forecast, by Vector Type (2017-2030)
11.5.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.5.6.3. Market Revenue and Forecast, by Workflow (2017-2030)
11.5.6.4. Market Revenue and Forecast, by End-use (2017-2030)
Chapter 12. Company Profiles
12.1. Merck KGaA
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Lonza
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Cobra Biologics Ltd.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Thermo Fisher Scientific
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Waisman Biomanufacturing
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Genezen
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. YPOSKESI
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Advanced BioScience Laboratories, Inc. (ABL, Inc.)
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Novasep Holding S.A.S
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
12.11. Orgenesis Biotech Israel Ltd (formerly ATVIO Biotech ltd.)
12.11.1. Company Overview
12.11.2. Product Offerings
12.11.3. Financial Performance
12.11.4. Recent Initiatives
12.12. Vigene Biosciences, Inc.
12.12.1. Company Overview
12.12.2. Product Offerings
12.12.3. Financial Performance
12.12.4. Recent Initiatives
12.13. General Electric Company (GE Healthcare)
12.13.1. Company Overview
12.13.2. Product Offerings
12.13.3. Financial Performance
12.13.4. Recent Initiatives
12.14. CEVEC Pharmaceuticals GmbH
12.14.1. Company Overview
12.14.2. Product Offerings
12.14.3. Financial Performance
12.14.4. Recent Initiatives
12.15. Batavia Biosciences B.V.
12.15.1. Company Overview
12.15.2. Product Offerings
12.15.3. Financial Performance
12.15.4. Recent Initiatives
12.16. Biovion oy
12.16.1. Company Overview
12.16.2. Product Offerings
12.16.3. Financial Performance
12.16.4. Recent Initiatives
12.17. Wuxi AppTec Co., Ltd.
12.17.1. Company Overview
12.17.2. Product Offerings
12.17.3. Financial Performance
12.17.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
Glossary of Terms